白斑治療薬市場：治療、疾患タイプ、薬剤タイプ、エンドユーザー、流通チャネル別-2025-2030年の世界予測

白斑治療薬市場は、2023年に14億5,000万米ドルと評価され、2024年には15億6,000万米ドルに達すると予測され、CAGR 8.43％で成長し、2030年には25億5,000万米ドルに達すると予測されています。

白斑治療薬には、色素沈着を特徴とする皮膚疾患である白斑の管理および回復を目的とした、さまざまな治療や介入が含まれます。この市場の範囲は、局所コルチコステロイド、カルシニューリン阻害剤、光線療法、新たな生物学的製剤や低分子化合物などの様々な薬理療法に及ぶ。これらの治療の必要性は、医学的および心理社会的ニーズの両方から生じており、白斑は重大な精神的苦痛や社会的スティグマにつながる可能性があるためです。適用範囲には、病院、皮膚科クリニック、在宅治療が含まれ、エンドユーザーには小児患者と成人患者の両方が含まれます。市場促進要因としては、尋常性白斑の有病率の増加、意識の高まり、新規治療薬の研究開発の急増などが挙げられます。JAK阻害剤や遺伝子治療などの革新的技術は、白斑治療における個別化医療に新たなフロンティアを提供する潜在的機会として浮上しています。このような機会を活用するための調査として、戦略的提携を活用し、新たな治療法の長期的な有効性と安全性プロファイルに焦点を当てた先進的研究に投資することが推奨されます。とはいえ、高額な治療費、白斑の病態に関する不完全な理解、規制上のハードルなど、市場の成長を阻害しかねない限界は依然として存在します。課題としては、患者の反応にばらつきがあること、症状が慢性的であることなどが挙げられ、適応治療プロトコルの継続的な研究が必要です。技術革新が必要な分野としては、非侵襲的診断ツールの開発、デジタルヘルスプラットフォームによる患者のアドヒアランス向上、皮膚の健康におけるマイクロバイオームの役割の探求などが挙げられます。白斑治療薬市場は、技術進歩の速さと患者中心のケアモデルへのシフトを特徴としており、ビジネスが大きく成長する可能性を示しています。この分野の利害関係者は、治療開発への包括的かつ進歩的なアプローチを促進するため、学術界、産業界、患者擁護団体間の連携強化に注力すべきです。

市場力学：急速に進化する白斑治療薬市場の主要市場インサイトを公開

白斑治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する白斑症例
  • 効果的な治療法に関する意識の高まり
• 市場抑制要因
  • 白斑治療薬および製品回収の潜在的リスク
• 市場機会
  • 効率的な白斑治療薬開発のための臨床試験および研究開発活動の増加
  • 白斑治療薬に対する有利な償還シナリオ
• 市場の課題
  • 白斑治療薬に関連する副作用のリスクと相まって、発展途上地域での治療法の普及が限定的であること

ポーターのファイブフォース：白斑治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：白斑治療薬市場における外部からの影響の把握

外部マクロ環境要因は、白斑治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析白斑治療薬市場における競合情勢の把握

白斑治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス白斑治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、白斑治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で白斑の症例が増加
    • 効果的な治療法の利用可能性に関する認識の高まり
  • 抑制要因
    • 白斑治療薬および製品リコールの潜在的リスク
  • 機会
    • 効率的な開発のための臨床試験と研究開発活動の増加白斑治療薬
    • 白斑治療薬の有利な償還シナリオ
  • 課題
    • 発展途上地域では治療法が限られており、白斑治療薬に関連する副作用のリスクも伴う
• 市場セグメンテーション分析
  • 治療：光療法における大きな技術的進歩
  • 疾患タイプ：分節性白斑疾患の有病率の上昇
  • 薬剤の種類：白斑治療におけるJAK阻害剤の有望な治療効果
  • エンドユーザー：コスト効率の良さから皮膚科クリニックへの関心が高まっている
  • 流通チャネル：オンライン薬局チャネルへの傾向の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 白斑治療薬市場治療別

• 光療法
• 外科手術
  • 細胞移植
  • 皮膚移植
• 局所治療

第7章 白斑治療薬市場：疾患タイプ別

• 非分節性白斑
• 分節性白斑

第8章 白斑治療薬市場薬の種類別

• カルシニューリン阻害剤
• カルシポトリエン
• コルチコステロイド
• JAK阻害剤

第9章 白斑治療薬市場：エンドユーザー別

• 病院
• 皮膚科クリニック

第10章 白斑治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの白斑治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の白斑治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの白斑治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • クリヌベル、白斑の国際第III相研究を開始
  • アッヴィ、ウパダシチニブ（リンヴォック）が白斑の第2相臨床試験で主要評価項目を達成し、プログラムが第3相に進んだことを発表
  • グレンマーク・ファーマシューティカルズ、タクロリムス軟膏0.03%のsANDA承認を取得
  • AVITA Medical、白斑患者の皮膚再色素沈着治療にRECELLのFDA承認を発表
  • 洞察、成人および青年の顔面を伴う非分節性白斑の治療としてオプゼルラ（ルキソリチニブ）クリームの欧州委員会承認を発表
  • マサチューセッツ工科大学チャン校、皮膚疾患の治療法開発のため、アルデナ・セラピューティクス社にsiRNA化学のライセンスを供与
  • カナダ保健省、エデサ・バイオテックの白斑治療試験を承認
  • アハムネ・バイオサイエンス、白斑治療薬の第1相臨床試験を完了
  • 洞察、メディクシィが支援するビラリス・セラピューティクスと抗IL-15RBモノクローナル抗体オーレモリマブ（VM6）の買収契約を発表
  • アルミラルとインセルム・トランスファートが白斑調査で契約を締結

企業一覧

• Clinuvel Pharmaceuticals Ltd.
• Merck KGaA
• ISSAR pharmaceuticals Pvt. Ltd.
• Vyne Therapeutics, Inc.
• Glenmark Pharmaceuticals Limited
• Organic Care Australia Pty Ltd.
• AbbVie Inc.
• TeVido BioDevices
• SESDERMA, S.L
• Biocon Limited
• Dermavant Sciences, Inc.
• Dr. Reddy's Laboratories Ltd.
• Array Skin Therapy
• Koninklijke Philips N.V.
• Astellas Pharma, Inc.
• Kernel Medical Equipment Co.,LTD
• Mylan N.V. by Viatris Inc.
• Stem Cell Care India
• SOMA Skin & Laser, LLC
• Accord Healthcare, Inc.
• Incyte Corporation
• Strides Pharma Science Limited
• Pierre Fabre S.A
• Panacea Biotec Limited
• The Daavlin Company
• Novartis AG
• Arcutis Biotherapeutics, Inc.
• Amgen Inc.
• JN Biosciences LLC
• Philadelphia Pharmaceuticals
• Clarify Health Solutions, Inc.
• Edesa Biotech, Inc.
• AVITA Medical, Inc.
• UNIZA Group
• Temprian Therapeutics Inc.
• Ahammune Biosciences Pvt. Ltd.
• Puneet Laboratories Pvt. Ltd.
• Bausch Health Companies Inc.
• Pfizer Inc.
• Nova Dermatology

LIST OF FIGURES

• FIGURE 1. VITILIGO THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. VITILIGO THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VITILIGO THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VITILIGO THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 50. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 82. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 88. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 191. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 192. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 193. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 214. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 215. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 216. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 217. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 220. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 221. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 222. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 223. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 224. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 280. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Vitiligo Therapeutics Market was valued at USD 1.45 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 8.43%, to USD 2.55 billion by 2030.

Vitiligo therapeutics encompass a range of medical treatments and interventions aimed at managing and potentially reversing the effects of vitiligo, a skin condition characterized by the loss of pigmentation. The scope of this market extends across various pharmacological therapies, such as topical corticosteroids, calcineurin inhibitors, phototherapy, and emerging biologics and small molecules. The necessity for these treatments stems from both medical and psychosocial needs, as vitiligo can lead to significant emotional distress and social stigmatization. The application spectrum covers hospital settings, dermatology clinics, and home-based treatments, with end-users including both pediatric and adult patients. Key market drivers include increasing prevalence of vitiligo, heightened awareness, and burgeoning research and development in novel therapeutics. Innovations such as JAK inhibitors and gene therapy emerge as potential opportunities, providing new frontiers for personalized medicine in vitiligo care. Recommendations for leveraging these opportunities involve tapping into strategic alliances and investing in advanced research focused on long-term efficacy and safety profiles of emerging therapies. Nevertheless, limitations persist, including high treatment costs, incomplete understanding of vitiligo's pathogenesis, and regulatory hurdles, which may impede market growth. Challenging factors also involve variability in patient response and the chronic nature of the condition, calling for ongoing research in adaptive treatment protocols. Areas ripe for innovation include developing non-invasive diagnostic tools, enhancing patient adherence through digital health platforms, and exploring the microbiome's role in skin health. The vitiligo therapeutics market is characterized by fast-evolving technological advances and a shift toward patient-centered care models, underscoring the potential for significant business growth. Stakeholders in this sector should focus on increasing collaboration between academia, industry, and patient advocacy groups to foster an inclusive and progressive approach to treatment development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vitiligo Therapeutics Market

The Vitiligo Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising cases of vitiligo across the globe
  • Growing awareness regarding the availability of effective treatments
• Market Restraints
  • Potential risk of vitiligo drug and product recall
• Market Opportunities
  • Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
  • Favorable reimbursement scenario for vitiligo therapeutics
• Market Challenges
  • Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Vitiligo Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vitiligo Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vitiligo Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vitiligo Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vitiligo Therapeutics Market

A detailed market share analysis in the Vitiligo Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vitiligo Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vitiligo Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Vitiligo Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Clinuvel Pharmaceuticals Ltd., Merck KGaA, ISSAR pharmaceuticals Pvt. Ltd., Vyne Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Organic Care Australia Pty Ltd., AbbVie Inc., TeVido BioDevices, SESDERMA, S.L, Biocon Limited, Dermavant Sciences, Inc., Dr. Reddy's Laboratories Ltd., Array Skin Therapy, Koninklijke Philips N.V., Astellas Pharma, Inc., Kernel Medical Equipment Co.,LTD, Mylan N.V. by Viatris Inc., Stem Cell Care India, SOMA Skin & Laser, LLC, Accord Healthcare, Inc., Incyte Corporation, Strides Pharma Science Limited, Pierre Fabre S.A, Panacea Biotec Limited, The Daavlin Company, Novartis AG, Arcutis Biotherapeutics, Inc., Amgen Inc., JN Biosciences LLC, Philadelphia Pharmaceuticals, Clarify Health Solutions, Inc., Edesa Biotech, Inc., AVITA Medical, Inc., UNIZA Group, Temprian Therapeutics Inc., Ahammune Biosciences Pvt. Ltd., Puneet Laboratories Pvt. Ltd., Bausch Health Companies Inc., Pfizer Inc., and Nova Dermatology.

Market Segmentation & Coverage

This research report categorizes the Vitiligo Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Light Therapy, Surgical Procedures, and Topical Treatment. The Surgical Procedures is further studied across Cell Transplant and Skin Graft.
• Based on Disease Type, market is studied across Nonsegmental Vitiligo and Segmental Vitiligo.
• Based on Drug Type, market is studied across Calcineurin Inhibitors, Calcipotriene, Corticosteroids, and JAK inhibitor.
• Based on End User, market is studied across Hospitals and Skin Clinics.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising cases of vitiligo across the globe
    • 5.1.1.2. Growing awareness regarding the availability of effective treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Potential risk of vitiligo drug and product recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
    • 5.1.3.2. Favorable reimbursement scenario for vitiligo therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Significant technological advancements in light therapies
  • 5.2.2. Disease Type: Rising prevalence of segmental vitiligo disorder
  • 5.2.3. Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management
  • 5.2.4. End User: Growing preference for skin clinics due to cost effectiveness
  • 5.2.5. Distribution Channel: Rising inclination towards online pharmacy channels
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vitiligo Therapeutics Market, by Treatment

• 6.1. Introduction
• 6.2. Light Therapy
• 6.3. Surgical Procedures
  • 6.3.1. Cell Transplant
  • 6.3.2. Skin Graft
• 6.4. Topical Treatment

7. Vitiligo Therapeutics Market, by Disease Type

• 7.1. Introduction
• 7.2. Nonsegmental Vitiligo
• 7.3. Segmental Vitiligo

8. Vitiligo Therapeutics Market, by Drug Type

• 8.1. Introduction
• 8.2. Calcineurin Inhibitors
• 8.3. Calcipotriene
• 8.4. Corticosteroids
• 8.5. JAK inhibitor

9. Vitiligo Therapeutics Market, by End User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Skin Clinics

10. Vitiligo Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Vitiligo Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Vitiligo Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Vitiligo Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Clinuvel Starts Global Phase III Vitiligo Study
  • 14.3.2. AbbVie Announces Upadacitinib (RINVOQ) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
  • 14.3.3. Glenmark Pharmaceuticals Receives sANDA Approval for Tacrolimus Ointment, 0.03%
  • 14.3.4. AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
  • 14.3.5. Incyte Announces European Commission Approval Of Opzelura (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
  • 14.3.6. UMass Chan Licensed siRNA chemistry to Aldena Therapeutics To Develop Therapies For Dermatological Diseases
  • 14.3.7. Health Canada Grants Approval for Edesa Biotech's Vitiligo Therapy Trial
  • 14.3.8. Ahammune Biosciences Completes Phase I Clinical Trial For Vitiligo Drug
  • 14.3.9. Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (VM6), An Anti-IL-15RB Monoclonal Antibody
  • 14.3.10. Almirall, Inserm Transfert Enter Agreement for Vitiligo Research

Companies Mentioned

• 1. Clinuvel Pharmaceuticals Ltd.
• 2. Merck KGaA
• 3. ISSAR pharmaceuticals Pvt. Ltd.
• 4. Vyne Therapeutics, Inc.
• 5. Glenmark Pharmaceuticals Limited
• 6. Organic Care Australia Pty Ltd.
• 7. AbbVie Inc.
• 8. TeVido BioDevices
• 9. SESDERMA, S.L
• 10. Biocon Limited
• 11. Dermavant Sciences, Inc.
• 12. Dr. Reddy's Laboratories Ltd.
• 13. Array Skin Therapy
• 14. Koninklijke Philips N.V.
• 15. Astellas Pharma, Inc.
• 16. Kernel Medical Equipment Co.,LTD
• 17. Mylan N.V. by Viatris Inc.
• 18. Stem Cell Care India
• 19. SOMA Skin & Laser, LLC
• 20. Accord Healthcare, Inc.
• 21. Incyte Corporation
• 22. Strides Pharma Science Limited
• 23. Pierre Fabre S.A
• 24. Panacea Biotec Limited
• 25. The Daavlin Company
• 26. Novartis AG
• 27. Arcutis Biotherapeutics, Inc.
• 28. Amgen Inc.
• 29. JN Biosciences LLC
• 30. Philadelphia Pharmaceuticals
• 31. Clarify Health Solutions, Inc.
• 32. Edesa Biotech, Inc.
• 33. AVITA Medical, Inc.
• 34. UNIZA Group
• 35. Temprian Therapeutics Inc.
• 36. Ahammune Biosciences Pvt. Ltd.
• 37. Puneet Laboratories Pvt. Ltd.
• 38. Bausch Health Companies Inc.
• 39. Pfizer Inc.
• 40. Nova Dermatology